Syngene International Limited — Updates, 10-02-2025: Press Release

Syngene International Limited has announced leadership changes, with Jonathan Hunt stepping down from his role as MD & CEO and the Board of Directors, effective immediately. Peter Bains has been appointed as the new CEO Designate. Hunt's tenure, which began in April 2016, saw significant contributions to the company's growth and value enhancement. Bains returns to the role following his previous position as CEO from June 2010 to March 2016, bringing over three decades of experience in the biotech and pharmaceutical sectors. His familiarity with the business and leadership capabilities position him well to guide Syngene in its next phase. The transition aims to maintain the momentum of Syngene’s strategic objectives and further bolster its operations in research, development, and manufacturing within the global pharmaceutical landscape.